End-stage Liver Disease
De novo liver cancer in liver transplant candidates warrants list advancement
Published in Hepatitis Weekly, June 28th, 2004
"Chronic end-stage liver disease is the most frequent indication for liver transplantation. Individuals with end stage cirrhosis, and therefore individuals on liver transplant lists, are at increased risk of developing a hepatic cancer. Those individuals on liver transplant lists also may represent the best group available for evaluating the current methods for screening and surveillance for the development of hepatic cancer as an examination of the explant liver provides a gold standard for tumor assessment," scientists in the United States report.
"Assuming that only...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-06-28)
More Articles from Hepatitis Weekly
- Addiction Medicine
Liver function test results for naltrexone patients may be misleading - Cancer Risk Factor
Genetic shifts emerge during hepatitis C virus-linked carcinogenesis - Immunology
Hepatitis C virus clears despite immunosuppression after liver transplantation - Stem Cell Research
Stem cell transplants reactivate resolved hepatitis B virus infections - Transplant Medicine
Hepatitis C contributes to persistent ascites after liver transplantation - Cancer Therapy
Liver cancer expert presents new data on SIR-Spheres - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
